
==== Front
Bone Marrow Transplant
Bone Marrow Transplant
Bone Marrow Transplantation
0268-3369
1476-5365
Nature Publishing Group UK London

38778148
2308
10.1038/s41409-024-02308-0
Article
Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials
http://orcid.org/0000-0002-1722-4807
Ganzel C. ganzelc@szmc.org.il

12
Wang Y. 3
Roopcharan K. 3
Sun Z. 3
Rowe J. M. 2
Fernandez H. F. 4
Paietta E. M. 5
Luger S. M. 6
http://orcid.org/0000-0002-1159-5607
Lazarus H. M. 7
Cripe L. D. 8
Douer D. 9
http://orcid.org/0000-0003-1473-813X
Wiernik P. H. 10
Tallman M. S. 11
http://orcid.org/0000-0002-9816-6302
Litzow M. R. 12
1 https://ror.org/03qxff017 grid.9619.7 0000 0004 1937 0538 Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
2 https://ror.org/03zpnb459 grid.414505.1 0000 0004 0631 3825 Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel
3 https://ror.org/02jzgtq86 grid.65499.37 0000 0001 2106 9910 Dana Farber Cancer Institute—ECOG-ACRIN Biostatistics Center, Boston, MA USA
4 grid.489080.d 0000 0004 0444 4637 Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines, USA
5 https://ror.org/05cf8a891 grid.251993.5 0000 0001 2179 1997 Albert Einstein College of Medicine, New York, NY USA
6 grid.25879.31 0000 0004 1936 8972 Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA USA
7 https://ror.org/051fd9666 grid.67105.35 0000 0001 2164 3847 Case Western Reserve University School of Medicine, Cleveland, OH USA
8 https://ror.org/00g1d7b60 0000 0004 0440 0167 Indiana University Simon Cancer Center, Indianapolis, IN USA
9 https://ror.org/01nmyfr60 grid.488628.8 0000 0004 0454 8671 Department of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA USA
10 https://ror.org/052nngb38 grid.478570.9 0000 0004 5902 7160 Cancer Research Foundation, Chappaqua, NY USA
11 https://ror.org/02yrq0923 grid.51462.34 0000 0001 2171 9952 Memorial Sloan Kettering Cancer Center, New York, NY USA
12 https://ror.org/02qp3tb03 grid.66875.3a 0000 0004 0459 167X Division of Hematology, Mayo Clinic, Rochester, MN USA
22 5 2024
22 5 2024
2024
59 9 12151223
7 8 2023
6 5 2024
8 5 2024
© The Author(s) 2024, corrected publication 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Several studies reported that patients with acute myeloid leukemia (AML) who remain in long-term remission after allogeneic or autologous transplant have a shorter life expectancy, compared to the general population. However, little is known about the life expectancy of adult long-term survivors of AML who were treated with chemotherapy alone without a transplant and there have been no comparisons with survival among the general population. The current study indicates that the life expectancy of AML patients who achieved and maintained CR for at least 3 years is shorter than expected for age in the US population. This was observed also in patients who did not undergo a transplant including those who have not relapsed during the entire long follow-up period. Thus, late relapse does not explain why patients without transplants have a shortened life expectancy. Taken together, these data strongly suggest that prior chemotherapy for the underlying AML is at least a major contributing factor for the known shortened life expectancy post-transplant.

Subject terms

Haematopoietic system
Epidemiology
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The treatment of fit newly diagnosed patients with acute myeloid leukemia (AML) is based on intensive chemotherapy with or without hematopoietic cell transplantation (HCT). Allogeneic HSCT (allo-HCT), despite its potent anti-leukemic effect, also entails a great risk of early and late complications, partly related to graft-versus-host disease (GvHD). Thus, it is not surprising that patients with AML who remain in remission after allogeneic HCT have a shorter life expectancy, compared with the general population [1–5]. A similar finding, though less intuitive, was reported by the EBMT regarding autologous HCT (auto-HCT) [6]. Nevertheless, much less is known about the life expectancy of patients with AML who are treated with chemotherapy alone without undergoing a transplant. There are some data regarding pediatric patients with AML who were treated by chemotherapy alone [7, 8] but the data regarding adult patients are scarce [9, 10] and, to the best of our knowledge, a comparison of the survival of this patient population to the general (“normal”) population has not been reported. The question driving the current study is whether patients who are cured without transplant and survive 3 years in remission have a similar life expectancy to the sex- and age-matched normal population and, if not, could this at least partially explain the lower life expectancy observed post-transplant.

Methods

Study population

Between 1984 and 2008, 3012 patients, aged ≥15 years, with untreated AML were enrolled on nine consecutive phase II or III ECOG-ACRIN-led clinical trials (E1490, E1900, E3483, E3489, E3993, E3997, E3999, E4995, PC486) [11–19]. The individual protocol details are summarized in Table 1. The current analysis relates to patients who participated in these studies, reached complete remission (CR), and were relapse-free at 3 years. The analysis focused on the mortality trends, from the 3-year time period onward. Patients were divided into three groups based on the therapy received: 1) patients who underwent an allo-HCT, 2) patients who received an auto-HCT, and 3) patients who received only intensive chemotherapy and did not undergo any transplant (no transplant).Table 1 AML protocols that were included in this study.

Protocol number (Study phase)	Induction	Consolidation	Activation-termination dates	Final accrual (Pts included)	Median follow-up year (95% CI)	
E3483 [11] (III)	Dauno, ARAC, 6TG (DAT)	Matched sibling: alloBMT.

Others: randomization to observation vs. maintenance vs. consolidation

	Mar 1984–Jan 1988	534 (445)	14.79 (14.39, 15.16)	
PC486 [12] (II)	DAT	Matched sibling: alloBMT

Others: autoBMT

	Apr 1987–Apr 1990	123 (98)	17.35 (15.37, 17.84)	
E3489 [13] (III)	Idarubicin, ARAC	Idarubicin, ARAC

HLA-matched or single-mismatched family member: alloBMT

Others were randomized to: autoBMT vs ARAC

	Feb 1990–Feb 1995	808 (753)	12.76 (12.53, 12.94)	
E1490 [14] (III)	Dauno, ARAC, and GM-CSF vs. placebo	ARAC + GM-CSF vs. placebo	Sep 1990–Nov 1992	124 (115)	10.05 (9.08, 10.92)	
E3993 [15] (III)	GM-CSF vs. placebo, ARAC

Randomization: Dauno vs. Mitoxantrone vs. Idarubicin

	Age < 70: ARAC + GM-CSF

Age > 70: ARAC + GM-CSF

	Apr 1993–Feb 1997	362 (343)	7.27 (5.66, 7.96)	
E4995 [19] (II)	Dauno, ARAC	Age < 51 + HLA-matched sibling: alloPBSCT

Others: ARAC, autoPBSCT

	Aug 1996–Feb 1997	66 (59)	6.28 (5.87, 6.39)	
E3997 [16] (II)	Dauno, ARAC + rhIL-11, GM-CSF	ARAC, rhIL-11, GM-CSF	June 1998–Apr 1999	36 (35)	8.02 (7.27, 8.25)	
E3999 [17] (III)	Dauno, ARAC and zosuquidar vs. placebo	ARAC

Dauno, ARAC and zosuquidar vs. placebo

	Jul 2002–Sep 2005	449 (421)	4.96 (4.88, 4.99)	
E1900 [18] (III)	Dauno 45 vs. 90, ARAC	Unfavorable/ intermediate risk or WBC > 100,000/µl + HLA-matched sibling: allo-HCT.

Others: ARAC, GO vs. no GO, auto-HCT

	Dec 2002–Nov 2008	657 (644)	8.28 (7.90, 8.65)	
allo allogeneic, ARAC cytosine arabinoside, auto autologous, BMT bone marrow transplant, dauno daunorubicin, GM-CSF granulocyte-macrophage colony-stimulating factor, GO gemtuzumab ozogamicin, HCT hematopoietic cell transplant, PB peripheral blood, 6TG 6-thioguanine.

Cytogenetics

The definition of the different cytogenetic risk groups, based mostly on the published ECOG cytogenetic classification [20], is as follows:

Favorable: inv(16)/t(16;16)/del(16q) with or without other chromosome abnormalities; t(8;21) with or without additional abnormalities.

Intermediate: +8; −Y; +6; del(9q); del(12p); Normal karyotype.

Unfavorable: −5/del(5q); −7/del(7q); inv(3q)/t(3;3); Abnormal 20q or 21q; Translocation involving 11q23, t(6;9); t(9;22); Abnormal 17p; Complex karyotype defined as 3 or more abnormalities.

Indeterminate: All other clonal chromosomal abnormalities with less than three abnormalities, inconclusive cytogenetic studies, and any karyotype other than favorable, intermediate, and unfavorable karyotype listed above.

Statistical considerations

Baseline characteristics of the patients in the three treatment groups were compared using Pearson’s chi-squared test if they were categorical and analysis of variance if they were continuous (Table 2).Table 2 Characteristics of the patients, at diagnosis, according to the 3 groups of treatment (allo-HSCT, auto-HSCT, no transplant).

Variable	Value	Allogenic transplant	Autologous transplant	No transplant	Total	P value (Chi Sq)	
N		78	110	315	503		
Age (years)	Mean (SD)	33.76 (10.66)	39.97 (11.88)	46.18(14.59)	42.9 (14.24)	<0.0001	
(Min, Max)	(16,54)	(18,60)	(15,79)	(15,79)	
Protocol	E1490	0	0	14 (100%)	14 (3%)		
E1900	15 (11%)	57 (41%)	68 (49%)	140 (28%)	
E3483	9 (13%)	0	59 (87%)	68 (14%)	
E3489	51 (28%)	36 (20%)	92 (51%)	179 (36%)	
E3993	0	0	13 (100%)	13 (3%)	
E3997	0	0	7 (100%)	7 (1%)	
E3999	0	0	34 (100%)	34 (7%)	
E4995	0	0	23 (100%)	23 (5%)	
PC486	3 (12%)	17 (68%)	5 (20%)	25 (5%)	
Sex	Male	34 (7%)	55 (11%)	149 (30%)	238 (47%)	0.686	
Female	44 (9%)	55 (11%)	166 (33%)	265 (53%)	
Performance status	0 or 1	71 (14%)	106 (21%)	280 (56%)	457 (91%)	0.064	
≥2	7 (1%)	4 (1%)	35 (7%)	46 (9%)	
Cytogenetics	Favorable	11 (2%)	29 (6%)	51 (10%)	91 (18%)	0.013	
Intermediate	34 (7%)	38 (8%)	108 (21%)	180 (36%)	
Unfavorable	10 (2%)	2 (0%)	21 (4%)	33 (7%)	
Indeterminate/missing	23 (5%)	41 (8%)	135 (27%)	199 (39%)	
White blood cell count (×102)	N	78	110	315	503	0.163	
Mean (SD)	30.58 (50.8)	27.88 (34.38)	22.48 (36)	24.92 (38.39)	
(Min, Max)	(0.6,366)	(0.2,178.9)	(0.3,360)	(0.2,366)	

Of the nine studies, only E1900, E3483, and E3489 included either an allo- or auto-HCT. Minimal cytogenetic information was available for patients enrolled on the earlier protocols (E1490, E3483, and PC486), which was consistent with the very limited cytogenetic data during this period.

A Kaplan–Meier plot is shown in Fig. 1 considering death as an event and censoring for patients alive at last contact. The three curves were compared using a log-rank test under the null hypothesis that the hazard of death was the same for all three groups over the course of follow-up beyond the 3-year relapse-free time. Cox proportional hazard regression models stratified by protocol were generated for overall survival. In the multivariate model (Table 1-SUP.), age, hemoglobin, platelet and white blood cell counts, bone marrow and peripheral blood blast percentages, cytogenetics, and ECOG performance status were adjusted and compared using a chi-square test under the null hypothesis that the hazard of death was equivalent in each group.Fig. 1 Overall survival by treatment group.

A Cox proportional hazard regression model comparing the relationship between survival and treatment of patients who achieved CR and are disease-free at 3 years.

Observed versus expected mortality

Patients were grouped together by age and gender. They were matched to a normal population mortality rate for that age and gender group (Table 3A–C). The normal population comparator of expected deaths was derived using mortality rates from the Centers for Disease Control and Prevention (CDC) which reports life tables by year [21–23]. The specific table used for each treatment group (allo-HCT, auto-HCT, and no transplant) was determined by calculating the median year for that treatment group, which is the year when the midpoint of the total person years of follow-up in each treatment group occurred. Person years were calculated by tabulating the number of years lived in each age group for all subjects. Each year of follow-up for a patient with AML was counted as one person year, and the corresponding bin matched their age at the time (i.e., a subject who was diagnosed at age 26 years and survived until age 31 would contribute five person years to the 25–34 age group). Person years were then multiplied by the mortality rate of the matched normal population. This gives expected deaths for each age group and gender in each treatment group [2]. Chi-square statistics were derived using expected deaths and observed deaths and then summed for each gender and treatment, allowing for a test of the null hypothesis that patients with AML followed the mortality rate of the normal population given their age, gender, and treatment after surviving and remaining relapse-free at 3 years from diagnosis.Table 3 Mortality tables.

A. Autologous transplant	
Age group	Sex	Number of subjects	Person years	Mortality rate	Expected deaths	Observed death	Chi-square	P-value	
15–19	M	3	6	0.00091	0.005	0	0.005	0.94	
20–24	M	9	34.7	0.00143	0.049	0	0.049	0.82	
25–34	M	18	98.3	0.00145	0.142	1	5.163	0.02	
35–44	M	24	134	0.00257	0.345	1	1.246	0.26	
45–54	M	31	166.5	0.00552	0.919	1	0.007	0.93	
55–64	M	24	140.9	0.0116	1.634	4	3.425	0.06	
65–74	M	4	7.9	0.02738	0.217	0	0.217	0.64	
15–19	F	1	2	0.00039	0.001	0	0.001	0.97	
20–24	F	8	24	0.00050	0.012	0	0.012	0.91	
25–34	F	16	92.9	0.00065	0.060	0	0.060	0.81	
35–44	F	28	127	0.00149	0.189	1	3.482	0.06	
45–54	F	33	203.2	0.00318	0.646	3	8.568	0.003	
55–64	F	25	137	0.00730	1.001	0	1.001	0.32	
65–74	F	8	18	0.01812	0.326	2	8.611	0.003	
B. Allogeneic Transplant	
15–19	M	5	9	0.00124	0.011	0	0.011	0.92	
20–24	M	11	42.5	0.00163	0.069	1	12.513	<0.001	
25–34	M	23	129.8	0.00204	0.265	1	2.037	0.15	
35–44	M	21	118.8	0.00327	0.389	3	17.531	<0.001	
45–54	M	11	59.8	0.00591	0.353	0	0.353	0.55	
55–64	M	6	22.2	0.01470	0.326	2	8.607	0.003	
65–74	M	0	0	NA	NA	0	NA	NA	
15–19	F	4	9.0	0.00045	0.004	0	0.004	0.95	
20–24	F	9	35.0	0.00051	0.018	0	0.018	0.56	
25–34	F	19	96.8	0.00075	0.073	0	0.073	0.79	
35–44	F	26	156.9	0.00144	0.225	1	2.662	0.1	
45–54	F	25	125.2	0.00328	0.411	3	16.326	<0.001	
55–64	F	9	50.3	0.00858	0.431	1	0.750	0.39	
65–74	F	3	7.5	0.01997	0.150	0	0.150	0.7	
C. No Transplant	
15–19	M	5	13	0.00125	0.016	0	0.016	0.9	
20–24	M	14	52	0.00161	0.084	0	0.084	0.77	
25–34	M	29	158.6	0.00203	0.322	1	1.426	0.2	
35–44	M	55	300.0	0.00332	0.995	6	25.192	<0.001	
45–54	M	71	367.2	0.00593	2.176	8	15.585	<0.001	
55–64	M	62	342.3	0.01432	4.901	11	7.589	0.006	
65–74	M	38	127.0	0.03316	4.211	10	7.958	0.005	
75–84	M	5	16.2	0.07458	1.210	1	0.036	0.85	
15–19	F	5	10.3	0.00044	0.005	0	0.005	0.95	
20–24	F	12	48.2	0.00051	0.024	1	38.963	<0.001	
25–34	F	36	170.6	0.00076	0.130	3	63.239	<0.001	
35–44	F	64	348.0	0.00146	0.508	2	4.387	0.036	
45–54	F	73	411.9	0.00328	1.349	4	5.207	0.022	
55–64	F	65	305.5	0.00838	2.560	10	21.621	<0.001	
65–74	F	45	182.2	0.01983	3.613	10	11.294	<0.001	
75–84	F	11	43.5	0.04824	2.097	2	0.0045	0.95	

The same US life tables from the CDC were used to get the survival of the matched normal population. The total population at the time of diagnosis for the normal population was set as the number of survivors in the life tables at the median age of diagnosis in the treatment group. The time of diagnosis was designated as year 1. The difference in survivor counts between each consecutive year and the preceding year was calculated to determine the number of deaths. Individuals who survived until year 19 were considered censored. Kaplan–Meier plots were used to compare overall survival to a matched US population (Fig. 2).Fig. 2 Overall survival of patients and normal population.

Kaplan–Meier curve showing the survival probabilities of patients (black) against normal population (red). 95% confidence bands are represented by dashed lines. a No transplant (black) vs. normal population (red). b Allogenic transplant (black) vs. normal population (red). c Autologous transplant (black) vs. normal population (red).

Results

Among 3012 patients with newly diagnosed AML who were enrolled on nine consecutive phase II or III ECOG-ACRIN clinical trials, 503 achieved a CR and were relapse-free at 3 years. These patients with a mean age of 42.9 years old (range: 15–79) were included in the analysis; 78 patients underwent an allo-HCT; 110—auto-HCT and 315 did not undergo transplantation. The general median follow-up was 10.97 years and the median follow-up for each study is summarized in Table 1 which compares the nine clinical trials. Table 2 summarizes and compares the characteristics of the patients in the three treatment groups, at diagnosis. The mean age was different between the groups (33.76, 39.97, and 46.18 for the allo-HCT, auto-HCT, and no-transplant groups, respectively, p < 0.001), as well as platelet count (p = 0.03), WBC count (p = 0.02) and cytogenetics (p = 0.01). The percentage of intermediate cytogenetic risk, for example, was only 7–8% among the allo- and auto-HCT patients and 21% among the no-transplant patients. The 10-year OS was 87.75% for the allo-HCT group, 88.28% for the auto-HCT group, and 77.97% for the no-transplant group. Although in the Kaplan–Meier curve (Fig. 1) the autologous transplant group had a decreased hazard of death when compared with the no transplant group, the multivariate Cox proportional hazard regression model presented non statistically significant different hazards for the two groups (HR (95%CI) = 0.63(0.30,1.32), p = 0.22, Table 1-SUP.).

Table 3 shows the life table for each of the 3 treatment groups. The CDC life tables were chosen according to the median year of each group, which was 2003, 1993, and 1994 for the auto-HCT, allo-HCT, and no transplant groups. As an example, patients from the no-HCT group (Table 3c), who are males in the age 35–44 (n = 55) were compared to the same age and gender persons in the matched CDC life table. The mortality rate for that group according to the CDC life table is 0.0332, so the expected death is 0.995 but the observed death among the group of no-transplant patients was six. The difference between the expected and observed death was statistically significant (p < 0.001). In every treatment group, patients had shorter survival compared with their age- and the gender-matched general population (p-value of 0.004 for the auto-HSCT group and <0.001 for both allo-HSCT and non-transplant groups).

Figure 2a–c compares the overall survival probability of the three treatment cohorts to the matched US normal populations. All three treatment groups have decreased survival probabilities compared with the matched normal population. In other words, patients with AML who have survived relapse-free for at least 3 years continue to have a greater mortality rate when compared with the normal population for up to 14 years.

Finally and crucially, it is important to show that relapse is not the only reason for the decreased life expectancy among the no-transplant patients. At the general median follow-up of 10.97 years, 35 relapses were observed, 5.7% (n = 2) were from the allo-HCT group, 8.6% (n = 3) from the auto-HCT and 85.7% (n = 30) from the no transplant group. Figure 3 shows the survival curves of the no transplant patients who relapsed beyond 3 years and of those who have not relapsed and compares them to the normal population. Both groups have decreased survival probabilities compared with the normal population. Figure 4 demonstrates that the mortality rate of patients who have not undergone transplant and have not relapsed during the entire follow-up period is still significantly greater than that of the normal population.Fig. 3 Overall survival of no-transplant patients by relapse status.

Kaplan–Meier curve showing the survival probabilities of no-transplant patients who relapsed beyond 3 years (blue) and no-transplant patients who did not relapse (black) against normal population (red). 95% confidence bands are represented by dashed lines.

Fig. 4 Mortality rate of patients who did not undergo a transplant and have not relapsed over the matched normal population.

The blue line represents the normal population. The red dots with their 95% confidence interval (in green) represent the mortality rate difference from the normal population. This figure demonstrates graphically that even patients who did not undergo a transplant and have not relapsed during the years of follow-up have a higher mortality rate compared to the normal population.

Discussion

It has long been established that the long-term life expectancy of patients undergoing an allogeneic HCT is lower than may be expected from a comparable “normal” population. This includes patients thought to be cured without evidence for any active chronic GvHD. While theories abound, a prevailing assumption is that this is in some way related to the inherent immunological reset that follows a successful allogeneic transplant [5, 24]. Such an assumption would not explain why a similar observation was reported following an autologous transplant. The possibility that factors unrelated to the transplant itself, such as the intensive chemotherapy given for the AML prior to the transplant, may contribute to these observations, formed the hypothesis for this study. To explore this hypothesis a detailed analysis was initiated to explore the actual life expectancy of patients with AML who did not receive any transplant and are ‘cured’ of their disease. Data from nine consecutive studies from the ECOG-ACRIN were used for this analysis.

The focus was on patients who received treatment for AML, entered a CR, and had not relapsed for 3 years. The data demonstrated that among the group of patients who did not have a transplant, the mortality rate was significantly higher than that of a comparable normal population, as determined from life tables of the CDC. The possible reasons for the higher mortality rate of patients who received only chemotherapy need to be elucidated. Although the rate of late relapse in AML is reported to be low [25, 26], such recurrences do occur and clearly may contribute to the increased mortality. In addition, late effects of chemotherapy [27], such as secondary malignancies [28], could explain part of the picture. Other predisposing factors, such as clonal hematopoiesis of indeterminate potential (CHIP) may increase the morbidity of different diseases such as atherosclerotic cardiovascular disease [29], cerebrovascular accidents (CVA) [30], and COPD [31]. In addition, other organ toxicities (cardiac, renal, or hepatic) may also increase the mortality rate. The precise cause of death in the ECOG-ACRIN clinical trials that formed the basis of this study was only captured in the very recent trials. It was thus important to demonstrate that relapse in and of itself cannot explain the entire picture. This led to the focus on the subgroup of patients who survived in CR for three years and have not relapsed throughout the entire long follow-up. This analysis demonstrated that even this selected cohort of patients has a higher mortality rate compared with the normal population.

Although the survival of patients with AML has changed over the period of this study, the cohorts of interest, after at least three years in CR, are likely to have a similar follow-up care. An analysis of each original study, by age and year, comprised tiny cohorts of patients, confounding any meaningful interpretation. At the same time, it remains entirely speculative whether advances in supportive care, such as vaccination strategies, anti-microbial prophylaxis, or improved cardiovascular screening, may impact the overall data in a group of patients spanning three decades.

Patients included in this analysis were treated over a period of time where there has been a marked evolution in transplantation practice and supportive care. Nevertheless, it seems likely that the issue remains relevant also in contemporary strategies [32]. Patients selected in this study are those who entered CR1 and maintained this CR for at least 3 years. We are not aware of any data that the biological likelihood of late relapse beyond 3 years, for those who were not transplanted and remained in CR throughout this period, has changed over the years (1984–2008) depending on the type of therapy that was used. It was therefore felt that selecting a larger population cohort, even if spread over more years, is reasonable and preferable to breaking this down into smaller groups with data that would be difficult to interpret.

In conclusion, the life expectancy of patients with AML who achieve and maintain CR for at least 3 years is shorter compared with the normal US population. This applies to patients who had a transplant, which has been known for a long time, but also to patients who did not have a transplant. For patients who were not transplanted, the reason for the shortened life expectancy is unknown but cannot be explained solely by late relapse. The etiology for the shortened life expectancy post HCT, after allowing for all known transplant complications and sequelae, has been a challenge. The data presented herein suggest at least a major contributing factor.

Supplementary information

Table 1-Sup

Supplementary information

The online version contains supplementary material available at 10.1038/s41409-024-02308-0.

Acknowledgements

This study was coordinated by the ECOG-ACRIN Cancer Research Group (Peter J. O’Dwyer, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported by the National Cancer Institute of the National Institutes of Health under award numbers: U10CA180820, U10CA180794, UG1CA189859, UG1CA233234, UG1CA180830, UG1CA233290, and UG1CA232760. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions

GC and RJM designed the study; GC, RJM, RK, SZ, FHF, PEM, LSM, LHM, CLD, DD, WPH, TMH and LMR contributed to the data interpretation; GC and RJM wrote the manuscript; WY, RK and SZ performed the statistical analyses; RJM, FHF, PEM, LSM, LHM, CLD, WPH, TMH and LMR were involved directly or indirectly in the care of patients; and all authors read and agreed on the final version of the manuscript.

Funding

Open access funding provided by Hebrew University of Jerusalem.

Data availability

All data generated or analysed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

All patients reported in the clinical trials in this article were part of the Eastern Cooperative Oncology Group (ECOG) of the National Cancer Institute (NCI) in the United States. All patients gave their approval to participate in these trials and all participating institutions were approved by their respective Institutional Review Boards (IRBs) as per the Declaration of Helsinki.

The original online version of this article was revised: The name of the author Yating Wang has been corrected.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

7/18/2024

A Correction to this paper has been published: 10.1038/s41409-024-02337-9
==== Refs
References

1. Pond GR Lipton JH Messner HA Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population Biol Blood Marrow Transpl 2006 12 422 9 10.1016/j.bbmt.2005.11.518
Pond GR, Lipton JH, Messner HA. Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. Biol Blood Marrow Transpl. 2006;12:422–9.10.1016/j.bbmt.2005.11.518
2. Martin PJ Counts GW Jr Appelbaum FR Lee SJ Sanders JE Deeg HJ Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation J Clin Oncol 2010 28 1011 6 10.1200/JCO.2009.25.6693 20065176
Martin PJ, Counts GW Jr, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28:1011–6.20065176 10.1200/JCO.2009.25.6693
3. Wingard JR Majhail NS Brazauskas R Wang Z Sobocinski KA Jacobsohn D Long-term survival and late deaths after allogeneic hematopoietic cell transplantation J Clin Oncol 2011 29 2230 9 10.1200/JCO.2010.33.7212 21464398
Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230–9.21464398 10.1200/JCO.2010.33.7212
4. Bhatia S Francisco L Carter A Sun CL Baker KS Gurney JG Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study Blood 2007 110 3784 92 10.1182/blood-2007-03-082933 17671231
Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784–92.17671231 10.1182/blood-2007-03-082933
5. Socie G Stone JV Wingard JR Weisdorf D Henslee-Downey PJ Bredeson C Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry N Engl J Med 1999 341 14 21 10.1056/NEJM199907013410103 10387937
Socie G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341:14–21.10387937 10.1056/NEJM199907013410103
6. Czerw T Labopin M Gorin NC Giebel S Blaise D Meloni G Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Cancer 2016 122 1880 7 10.1002/cncr.29990 27018549
Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Meloni G, et al. Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122:1880–7.27018549 10.1002/cncr.29990
7. Molgaard-Hansen L Mottonen M Glosli H Jonmundsson GK Abrahamsson J Hasle H Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia Br J Haematol 2011 152 623 30 10.1111/j.1365-2141.2010.08554.x 21241281
Molgaard-Hansen L, Mottonen M, Glosli H, Jonmundsson GK, Abrahamsson J, Hasle H, et al. Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia. Br J Haematol. 2011;152:623–30.21241281 10.1111/j.1365-2141.2010.08554.x
8. Mulrooney DA Dover DC Li S Yasui Y Ness KK Mertens AC Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study Cancer 2008 112 2071 9 10.1002/cncr.23405 18327823
Mulrooney DA, Dover DC, Li S, Yasui Y, Ness KK, Mertens AC, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer. 2008;112:2071–9.18327823 10.1002/cncr.23405
9. Major CK Kantarjian H Sasaki K Borthakur G Kadia T Pemmaraju N Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years Leuk Lymphoma 2020 61 3120 7 10.1080/10428194.2020.1802450 32755333
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, et al. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020;61:3120–7.32755333 10.1080/10428194.2020.1802450
10. Vasu S Kohlschmidt J Mrozek K Eisfeld AK Nicolet D Sterling LJ Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission Blood Adv 2018 2 1645 50 10.1182/bloodadvances.2017015222 29991495
Vasu S, Kohlschmidt J, Mrozek K, Eisfeld AK, Nicolet D, Sterling LJ, et al. Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2:1645–50.29991495 10.1182/bloodadvances.2017015222
11. Cassileth PA Lynch E Hines JD Oken MM Mazza JJ Bennett JM Varying intensity of postremission therapy in acute myeloid leukemia Blood 1992 79 1924 30 10.1182/blood.V79.8.1924.1924 1562720
Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 1992;79:1924–30.1562720 10.1182/blood.V79.8.1924.1924
12. Cassileth PA Andersen J Lazarus HM Colvin OM Bennett JM Stadtmauer EA Autologous bone marrow transplant in acute myeloid leukemia in first remission J Clin Oncol 1993 11 314 9 10.1200/JCO.1993.11.2.314 8426209
Cassileth PA, Andersen J, Lazarus HM, Colvin OM, Bennett JM, Stadtmauer EA, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol. 1993;11:314–9.8426209 10.1200/JCO.1993.11.2.314
13. Cassileth PA Harrington DP Appelbaum FR Lazarus HM Rowe JM Paietta E Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission N Engl J Med 1998 339 1649 56 10.1056/NEJM199812033392301 9834301
Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–56.9834301 10.1056/NEJM199812033392301
14. Rowe JM Andersen JW Mazza JJ Bennett JM Paietta E Hayes FA A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490) Blood 1995 86 457 62 10.1182/blood.V86.2.457.bloodjournal862457 7605984
Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457–62.7605984 10.1182/blood.V86.2.457.bloodjournal862457
15. Rowe JM Neuberg D Friedenberg W Bennett JM Paietta E Makary AZ A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group Blood 2004 103 479 85 10.1182/blood-2003-05-1686 14512295
Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, Makary AZ, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479–85.14512295 10.1182/blood-2003-05-1686
16. Cripe LD Rader K Tallman MS Gordon MS Paietta E Bennett J Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997 Leuk Res 2006 30 823 7 10.1016/j.leukres.2005.11.006 16413056
Cripe LD, Rader K, Tallman MS, Gordon MS, Paietta E, Bennett J, et al. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997. Leuk Res. 2006;30:823–7.16413056 10.1016/j.leukres.2005.11.006
17. Cripe LD Uno H Paietta EM Litzow MR Ketterling RP Bennett JM Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 Blood 2010 116 4077 85 10.1182/blood-2010-04-277269 20716770
Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010;116:4077–85.20716770 10.1182/blood-2010-04-277269
18. Fernandez HF Sun Z Yao X Litzow MR Luger SM Paietta EM Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 2009 361 1249 59 10.1056/NEJMoa0904544 19776406
Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–59.19776406 10.1056/NEJMoa0904544
19. Cassileth PA Lee SJ Litzow MR Miller KB Stadtmauer EA Tallman MS Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995) Leuk Lymphoma 2005 46 55 61 10.1080/10428190412331283288 15621781
Cassileth PA, Lee SJ, Litzow MR, Miller KB, Stadtmauer EA, Tallman MS, et al. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). Leuk Lymphoma. 2005;46:55–61.15621781 10.1080/10428190412331283288
20. Slovak ML Kopecky KJ Cassileth PA Harrington DH Theil KS Mohamed A Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 2000 96 4075 83 10.1182/blood.V96.13.4075 11110676
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–83.11110676 10.1182/blood.V96.13.4075
21. Vital Statistics of the United States, 1993. Life Tables, Vol. II, Section 6. p. 28. (PHS) 97–1104.
22. United States Life Tables, 2003. NVSR. Vol. 54, number 14. p. 40 (PHS) 2005–1120.
23. Vital Statistics of the United States, 1994. Life Tables, Vol. II, Section 6. p. 28 (PHS) 98–1104.
24. Thomas ED Does bone marrow transplantation confer a normal life span? N Engl J Med 1999 341 50 1 10.1056/NEJM199907013410110 10391754
Thomas ED. Does bone marrow transplantation confer a normal life span? N Engl J Med. 1999;341:50–1.10391754 10.1056/NEJM199907013410110
25. Watts JM Wang XV Litzow MR Luger SM Lazarus HM Cassileth PA Younger adults with acute myeloid leukemia in remission for >/= 3 years have a high likelihood of cure: the ECOG experience in over 1200 patients Leuk Res 2014 38 901 6 10.1016/j.leukres.2014.05.018 24986381
Watts JM, Wang XV, Litzow MR, Luger SM, Lazarus HM, Cassileth PA, et al. Younger adults with acute myeloid leukemia in remission for >/= 3 years have a high likelihood of cure: the ECOG experience in over 1200 patients. Leuk Res. 2014;38:901–6.24986381 10.1016/j.leukres.2014.05.018
26. Verma D Kantarjian H Faderl S O’Brien S Pierce S Vu K Late relapses in acute myeloid leukemia: analysis of characteristics and outcome Leuk Lymphoma 2010 51 778 82 10.3109/10428191003661852 20196624
Verma D, Kantarjian H, Faderl S, O’Brien S, Pierce S, Vu K, et al. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma. 2010;51:778–82.20196624 10.3109/10428191003661852
27. Yeh JM Ward ZJ Chaudhry A Liu Q Yasui Y Armstrong GT Life expectancy of adult survivors of childhood cancer over 3 decades JAMA Oncol 2020 6 350 7 10.1001/jamaoncol.2019.5582 31895405
Yeh JM, Ward ZJ, Chaudhry A, Liu Q, Yasui Y, Armstrong GT, et al. Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol. 2020;6:350–7.31895405 10.1001/jamaoncol.2019.5582
28. Morton LM, Onel K, Curtis RE, Hungate EA, Armstrong GT. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book. 2014;34:e57–67.
29. Jaiswal S Natarajan P Silver AJ Gibson CJ Bick AG Shvartz E Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease N Engl J Med 2017 377 111 21 10.1056/NEJMoa1701719 28636844
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21.28636844 10.1056/NEJMoa1701719
30. Bhattacharya R Zekavat SM Haessler J Fornage M Raffield L Uddin MM Clonal hematopoiesis is associated with higher risk of stroke Stroke 2022 53 788 97 10.1161/STROKEAHA.121.037388 34743536
Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke. 2022;53:788–97.34743536 10.1161/STROKEAHA.121.037388
31. Miller PG Qiao D Rojas-Quintero J Honigberg MC Sperling AS Gibson CJ Association of clonal hematopoiesis with chronic obstructive pulmonary disease Blood 2022 139 357 68 10.1182/blood.2021013531 34855941
Miller PG, Qiao D, Rojas-Quintero J, Honigberg MC, Sperling AS, Gibson CJ, et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood. 2022;139:357–68.34855941 10.1182/blood.2021013531
32. El-Cheikh J Bidaoui G Saleh M Moukalled N Abou Dalle I Bazarbachi A Venetoclax: a new partner in the novel treatment era for acute myeloid leukemia and myelodysplastic syndrome Clin Hematol Int 2023 5 143 54 10.1007/s44228-023-00041-x 37071328
El-Cheikh J, Bidaoui G, Saleh M, Moukalled N, Abou Dalle I, Bazarbachi A. Venetoclax: a new partner in the novel treatment era for acute myeloid leukemia and myelodysplastic syndrome. Clin Hematol Int. 2023;5:143–54.37071328 10.1007/s44228-023-00041-x
